PET measurement of FK506 concentration in a monkey model of stroke

Nuclear Medicine and Biology

Volumn 34, Issue 6, 2007, Pages 703-707

  Murakami, Yoshihiro ^a,b   Takamatsu, Hiroyuki ^a   Noda, Akihiro ^a,b   Osoda, Kazuhiko ^b   Nishimura, Shintaro ^a,b  

^a Medical and Pharmacological Research Center Foundation   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Brain concentration; FK506; Neuroprotectant; Positron emission tomography; Stroke

Indexed keywords

TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN ISCHEMIA; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG BLOOD LEVEL; DRUG PENETRATION; MACACA; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; STROKE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; BRAIN ISCHEMIA; FUNCTIONAL LATERALITY; IMMUNOSUPPRESSIVE AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STROKE; TACROLIMUS;

EID: 34547839774     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.05.007     Document Type: Article

References (22)

1. Sharkey J., and Butcher S.P. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 371 (1994) 336-339
2. Maeda M., Furuichi Y., Ueyama N., et al. A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: increased neuroprotective efficacy and extended therapeutic time window. J Cereb Blood Flow Metab 22 (2002) 1205-1211
3. Butcher S.P., Henshall D.C., Teramura Y., Iwasaki K., and Sharkey J. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J Neurosci 17 (1997) 6939-6946
4. Furuichi Y., Katsuta K., Maeda M., et al. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res 965 (2003) 137-145
5. Takamatsu H., Tsukada H., Noda A., et al. FK506 attenuates early ischemic neuronal death in a monkey model of stroke. J Nucl Med 42 (2001) 1833-1840
6. Furuichi Y., Maeda M., Moriguchi A., et al. Tacrolimus, a potential neuroprotective agent, ameliorates ischemic brain damage and neurologic deficits after focal cerebral ischemia in nonhuman primates. J Cereb Blood Flow Metab 23 (2003) 1183-1194
7. Murakami Y., Takamatsu H., Noda A., et al. Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. J Nucl Med 45 (2004) 1946-1949
8. Saeki T., Ueda K., Tanigawara Y., Hori R., and Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268 (1993) 6077-6080
9. Watanabe M., Okada H., Shimizu K., et al. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci 44 (1997) 1277-1282
10. 11C-labeled FK506 for positron emission tomography. Tetrahedron Lett 44 (2003) 641-644
11. Cross D.J., Minoshima S., Nishimura S., Noda A., Tsukada H., and Kuhl D.E. Three-dimensional stereotactic surface projection analysis of macaque brain PET: development and initial applications. J Nucl Med 41 (2000) 1879-1887
12. Kawai H., Umemura K., and Nakashima M. Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Jpn J Pharmacol 69 (1995) 143-148
13. Maeda M., Takamatsu H., Furuichi Y., et al. Characterization of a novel thrombotic middle cerebral artery occlusion model in monkeys that exhibits progressive hypoperfusion and robust cortical infarction. J Neurosci Methods 146 (2005) 106-115
14. Pappata S., Fiorelli M., Rommel T., et al. PET study of changes in local brain hemodynamics and oxygen metabolism after unilateral middle cerebral artery occlusion in baboons. J Cereb Blood Flow Metab 13 (1993) 416-424
15. Heiss W.D., Graf R., Wienhard K., et al. Dynamic penumbra demonstrated by sequential multitracer PET after middle cerebral artery occlusion in cats. J Cereb Blood Flow Metab 14 (1994) 892-902
16. Heiss W.D., Graf R., Lottgen J., et al. Repeat positron emission tomographic studies in transient middle cerebral artery occlusion in cats: residual perfusion and efficacy of postischemic reperfusion. J Cereb Blood Flow Metab 17 (1997) 388-400
17. Young A.R., Sette G., Touzani O., et al. Relationships between high oxygen extraction fraction in the acute stage and final infarction in reversible middle cerebral artery occlusion: an investigation in anesthetized baboons with positron emission tomography. J Cereb Blood Flow Metab 16 (1996) 1176-1188
18. Touzani O., Young A.R., Derlon J.M., et al. Sequential studies of severely hypometabolic tissue volumes after permanent middle cerebral artery occlusion. A positron emission tomographic investigation in anesthetized baboons. Stroke 26 (1995) 2112-2119
19. Takamatsu H., Tsukada H., Kakiuchi T., Nishiyama S., Noda A., and Umemura K. Detection of reperfusion injury using PET in a monkey model of cerebral ischemia. J Nucl Med 41 (2000) 1409-1416
20. Chan P.H. Role of oxidants in ischemic brain damage. Stroke 27 (1996) 1124-1129
21. Stanimirovic D., and Satoh K. Inflammatory mediators of cerebral endothelium: a role in ischemic brain inflammation. Brain Pathol 10 (2000) 113-126
22. Albayrak S., Zhao Q., Siesjo B.K., and Smith M.L. Effect of transient focal ischemia on blood-brain barrier permeability in the rat: correlation to cell injury. Acta Neuropathol (Berl) 94 (1997) 158-163